The present disclosure provides a method for cryopreserving corneal endothelial cells and/or corneal endothelial-like cells, and a freezing preparation for corneal endothelial cells and/or corneal endothelial-like cells. The present disclosure provides a method for preserving corneal endothelial cells and/or corneal endothelial-like cells, wherein the method includes: a freezing step for freezing unfrozen corneal endothelial cells and/or corneal endothelial-like cells, the freezing step including at least one stage in which the temperature is reduced at a rate of less than 1 C./min when the temperature is changed from the unfrozen temperature to the freezing target temperature; and, if necessary, a step for maintaining the corneal endothelial cells and/or the corneal endothelial-like cells in a frozen state.

This disclosure is related to methods of preserving biological samples such as organs, and tissue. The present disclosure relates to methods of subzero preservation of biological tissue samples, such as entire organs from mammals, e.g., humans. The present disclosure is based, at least in part, on the discovery that biological tissue samples can be supercooled while minimizing formation of ice crystals by reducing liquid-air interfaces and lowering the melting point of the tissue samples, e.g., organs, or liquid in the tissue samples by use of cryoprotective agents while ensuring uniform distribution of cryoprotective agents throughout the biological sample by using improved perfusion techniques.

The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

Disclosed is a device for use in freezing at least part of a biological sample in a receptacle, e.g. a vial or a cryopreservation bag, the device comprising: a base; and a receptacle holder comprising: a first part configured to, with the receptacle held by the receptacle holder during cooling of the base using a cooler device, withdraw heat energy from a first portion of the receptacle at a first heat withdrawal rate; and a second part configured such that, with the receptacle held by the receptacle holder during cooling of the base using the cooler device, a second heat withdrawal rate of heat energy withdrawal from a second portion of the receptacle via the second part is less than the first heat withdrawal rate. A temperature gradient may be established in the sample to enable progressive solidification to occur in the sample. A receptable for use in freezing a biological sample, and a freezing method are disclosed also.

The present invention provides methods for cryopreserving a population of cells with improved cell viability. In some aspects, the method comprises contacting a population of cells with a peptoid polymer comprising one or more polar peptoid monomers, e.g., formulated in a cryoprotectant solution, and cooling the population of cells at a temperature of from 0 C. to about 20 C. for a time period of at least about 3 hours to produce a population of supercooled cells. The supercooling methods of the present invention provide excellent post-thaw cell survival and recovery. In certain embodiments, the population of cells is present in a tissue or an organ that is cryopreserved by performing the supercooling methods of the present invention.

The present invention provides methods for cryopreserving a population of cells with improved cell viability. In some aspects, the method comprises contacting a population of cells with a peptoid polymer comprising one or more polar peptoid monomers, e.g., formulated in a cryoprotectant solution, and cooling the population of cells at a temperature of from 0 C. to about 20 C. for a time period of at least about 3 hours to produce a population of supercooled cells. The supercooling methods of the present invention provide excellent post-thaw cell survival and recovery. In certain embodiments, the population of cells is present in a tissue or an organ that is cryopreserved by performing the supercooling methods of the present invention.

In accord with the present invention, the fertility quality of an ejaculate can be determined by assaying sperm, in aliquots of the ejaculate or of an ejaculate produced previously by the same male, at intervals over a period of time. Fertility quality is determined by the number of times the level of expression of a marker on the sperm goes through a maximum level of expression during the period of time and if desired by sperm state and fertilization procedure used. The marker should be capable of correlation with the level of Fc receptor (FcR) expression on the sperm. The fertility quality of the ejaculate is related to the number of times a maximum level of expression is reached.

Systems, devices and methods for shaping a liquid material within a cryostorage bag while undergoing a freezing procedure.

The present invention discloses cryopreserved recombinant cells for screening drug candidates that transiently overexpress one or more drug transporter proteins and/or drug metabolizing enzymes. Advantageously, such cells provide a cost-efficient consumable product that streamlines the process of screening whether drug candidates are substrates or inhibitors of drug transporter proteins and/or drug metabolizing enzymes.